Formulation and Evaluation of Liquisolid Compacts for Olmesartan Medoxomil
Table 1
Formulations of olmesartan liquisolid compacts.
No.
Drug conc. in vehicle (%w/w)a
Avicel () (mg)
Fujicalin () (mg)
Neusilin () (mg)
Aerosil () (mg)
Liquid load factor ()
Disintegrantc (mg)
Unit dose (mg)
LSA 1
20
5
285.7
—
—
57.4
0.28
26.57
469.6
LSA 2
20
10
370.3
—
—
37.0
0.27
30.43
537.4
LSA 3
20
15
416.6
—
—
27.7
0.24
32.65
577
LSA 4
40
5
178.5
—
—
35.7
0.28
15.8
280
LSA 5
40
10
185.1
—
—
18.5
0.27
15.2
268.8
LSA 6
40
15
208.3
—
—
13.8
0.24
16.3
288.4
LSA 7
20
5
—
168
—
34
0.595
18.12
320.2
LSA 8
20
10
—
194
—
19.4
0.515
18.8
332.2
LSA 9
20
15
—
205
—
13.6
0.488
19
337.6
LSA 10
40
5
—
84
—
16.8
0.595
9
160
LSA 11
40
10
—
97
—
9.7
0.515
9.4
166
LSA 12
40
15
—
102
—
7
0.488
9.5
168.8
LSA 13
20
5
—
—
100
20
1.00
13.2
233.2
LSA 14
20
10
—
—
108
10.8
0.925
13.1
232
LSA 15
20
15
—
—
111.3
7.4
0.898
13
231.7
LSA 16
40
5
—
—
50
10
1.00
6.6
116.6
LSA 17
40
10
—
—
54
5.4
0.925
6.5
115.9
LSA 18
40
15
—
—
55.6
3.7
0.898
6.5
115.8
An appropriate amount of liquid medication containing 20 mg drug was incorporated in each tablet. = Carrier : Coating ratio; .
cIncludes 6% (w/w) per tablet of the disintegrant—croscarmellose sodium.
